氨曲南用于下呼吸道感染患者的全球临床试验总结。
Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections.
作者信息
Swabb E A, Cone C O, Muir J G
出版信息
Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S675-8. doi: 10.1093/clinids/7.supplement_4.s675.
Aztreonam was administered to 226 patients with lower respiratory tract infections--primarily pneumonia (181 patients)--due to gram-negative bacilli. The clinical response rate was 93%, and the microbiologic cure rate was 78%. Most patients received 1-g or 2-g intravenous doses of aztreonam three times daily for at least five days. Ninety-eight of the 226 patients were involved in a randomized comparison of aztreonam with tobramycin; the latter drug was administered to a group of 34 patients. The overall microbiologic cure rates for the two drugs were 86% and 71%, respectively. Aztreonam is effective for the treatment of lower respiratory tract infections due to susceptible gram-negative bacilli.
226例因革兰氏阴性杆菌引起下呼吸道感染（主要为肺炎，共181例）的患者接受了氨曲南治疗。临床有效率为93%，微生物学治愈率为78%。大多数患者接受每日3次、每次1克或2克静脉注射氨曲南，至少持续5天。226例患者中有98例参与了氨曲南与妥布霉素的随机对照试验；后者被给予一组34例患者。两种药物的总体微生物学治愈率分别为86%和71%。氨曲南对治疗由敏感革兰氏阴性杆菌引起的下呼吸道感染有效。
Zotero 插件